Cyclo Therapeutics, Inc. - CYTH STOCK NEWS

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) has announced a definitive securities purchase agreement to sell 2,608,696 shares of common stock at $1.61 each in a registered direct offering, expected to close around January 3, 2023, generating approximately $4.2 million in gross proceeds. Concurrently, the company will issue series A-1 and A-2 warrants, each exercisable at $1.36 per share. The funds will primarily support the pivotal Phase III trial for Trappsol® Cyclo™ in treating Niemann-Pick Disease Type C.

Cyclo Therapeutics (NASDAQ: CYTH) reported its Q3 2022 earnings, highlighting significant advancements in its clinical programs for Trappsol^® Cyclo™. The company launched a Phase 2b study for early Alzheimer’s Disease, commencing patient enrollment and site activation. Research and development expenses rose by 55% to approximately $2.9 million, with a net loss of $4.2 million. As of September 30, 2022, cash reserves stood at $4.3 million. The firm remains on track for further developments in both Alzheimer’s and Niemann-Pick Disease treatment programs.

Cyclo Therapeutics has published positive results from its Phase 1 trial of Trappsol® Cyclo™ for treating Niemann-Pick Disease type C1 (NPC1), addressing cholesterol accumulation in cells. The data, published in Molecular Genetics and Metabolism, highlighted the treatment's safety and efficacy, showing reduced cholesterol in the liver and improved biomarkers in both peripheral and central nervous systems.

The ongoing pivotal Phase 3 study, TransportNPC™, will involve at least 93 patients across 23 centers in 9 countries, further evaluating the drug's potential benefits.

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) has initiated its Phase 2b clinical trial of Trappsol® Cyclo™ to treat early Alzheimer’s disease, with patient enrollment underway. The study is randomized, placebo-controlled, and will involve approximately 120 patients over 6 months to evaluate the drug's safety and potential efficacy. Experts highlight the investigational drug's ability to stabilize disease progression and its access to the central nervous system as critical factors. The company is committed to developing innovative treatments for Alzheimer's and similar diseases.

Cyclo Therapeutics (NASDAQ: CYTH) announces progress in its clinical programs, specifically for Trappsol® Cyclo™, targeting Alzheimer’s and Niemann-Pick Disease Type C1. The company plans to begin patient enrollment and dosing for a Phase 2 Alzheimer’s study by year-end 2022. Concurrently, the ongoing pivotal Phase 3 study (TransportNPC™) aims to enroll 93 patients across nine countries. Additionally, Cyclo plans to participate in the NPUK Annual Family Conference on October 6-7, 2022, to raise awareness about Niemann-Pick Disease.

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced that CEO N. Scott Fine will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York City, taking place from September 12-14, 2022. In addition to the presentation, the management team will hold virtual one-on-one meetings with qualified investors. A video webcast of the presentation will be available on-demand starting September 12 at 7:00 AM ET and accessible for 90 days on Cyclo Therapeutics' website.

Cyclo Therapeutics is focused on developing therapies for rare diseases, including Niemann-Pick Disease Type C.

Cyclo Therapeutics (CYTH) reported a net loss of $3.5 million for Q2 2022, with R&D expenses decreasing 29% to $1.9 million. The company is advancing its clinical programs for Trappsol® Cyclo™, targeting Niemann-Pick Disease and Alzheimer’s Disease. The Phase 2 study for Alzheimer’s is set to begin by year-end, while the pivotal Phase 3 study for Niemann-Pick aims to enroll at least 93 patients across 9 countries. Cyclo Therapeutics holds Orphan Drug Designation in both the U.S. and EU for NPC1 and has a cash reserve of $7.5 million.

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) announced that Dr. Lise Kjems, Chief Medical Officer, will present at the 2022 China Niemann Pick Medical Exchange on August 13, 2022, in Xiamen, China. The event focuses on Niemann-Pick Disease Type C (NPC) and the company's clinical development of Trappsol^® Cyclo™. Dr. Kjems emphasized the need for novel therapies for NPC patients in China, highlighting ongoing research to advance treatment for this rare genetic disease.

Cyclo Therapeutics, Inc. (NASDAQ: CYTH) will participate in the 30th Annual NNPDF Family Support & Medical Conference from July 28-31, 2022, in Orlando, FL. The company aims to engage with the Niemann-Pick disease community, showcasing its Trappsol® Cyclo™ IV formulation for treating Niemann-Pick Disease Type C (NPC). Key presentations include a discussion on July 30 at 1:30 PM ET and an overview of its clinical program on July 31 at 8:45 AM ET. For more details, visit the conference website.